ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
about
High-throughput 1,536-well fluorescence polarization assays for α(1)-acid glycoprotein and human serum albumin bindingA high-throughput 1,536-well luminescence assay for glutathione S-transferase activity.A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain.DDPC: Dragon Database of Genes associated with Prostate CancerArylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosisUse of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic moleculesSimulation-Based Approaches for Determining Membrane Permeability of Small CompoundsEfflux transporters in the blood-brain interfaces--in vitro and in vivo methods and correlations.Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies.In silico and in vitro prediction of gastrointestinal absorption from potential drug eremantholide C.Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly.Re-evaluation of the role of P-glycoprotein in in vitro drug permeability studies with the bovine brain microvessel endothelial cells.A Microfluidic Platform for the Characterisation of CNS Active Compounds.
P2860
Q28483928-17A885E5-019D-4506-880C-CC646E6E4770Q33525153-190F466C-5BB0-40F5-A156-667679468CFCQ33968508-385D3E2D-F18A-4C94-99DE-D18F0C871145Q34456593-003C17D7-BE25-4745-8D0C-CDDBDF8E5C4CQ34459374-36508B72-796F-4E96-8E83-D8D6FD15ACA9Q35688446-16AC8F23-119E-49D3-BA3F-2937FE2C6BF1Q36841904-9CF644A8-0858-45EA-83AC-60E55DD2ACD9Q37614213-747F3F3B-F318-4D57-BBE9-BE7F582F504AQ37991010-1A56050A-2A5C-46F8-A8B7-14042A2EB7B5Q38067621-D852721E-9F8F-4F1F-A254-F317CEC1E347Q38672619-4781CC46-F621-42F7-BA00-2B0095091F60Q40226025-55F2BB6E-06DA-4E9D-93AB-904164631E78Q43879475-EAE487B0-28F6-42EE-80A9-ECE7F60F8C3CQ44462403-A334D2C4-74AB-400F-A6C8-02D1E4FFFBC8
P2860
ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
ADDME--Avoiding Drug Developme ...... tem drug discovery perspective
@ast
ADDME--Avoiding Drug Developme ...... tem drug discovery perspective
@en
type
label
ADDME--Avoiding Drug Developme ...... tem drug discovery perspective
@ast
ADDME--Avoiding Drug Developme ...... tem drug discovery perspective
@en
prefLabel
ADDME--Avoiding Drug Developme ...... tem drug discovery perspective
@ast
ADDME--Avoiding Drug Developme ...... tem drug discovery perspective
@en
P2093
P2860
P1433
P1476
ADDME--Avoiding Drug Developme ...... tem drug discovery perspective
@en
P2093
Aloise Mabondzo
Alzheimer's Drug Discovery Foundation
Katya Tsaioun
Michel Bottlaender
P2860
P2888
P356
10.1186/1471-2377-9-S1-S1
P478
P577
2009-06-12T00:00:00Z
P5875
P6179
1028029926